Chlamydia Trachomatis Infection Doubles the Risk for Ovarian Cancer

TON - May 2018, Vol 11, No 2 - Ovarian Cancer
Phoebe Starr

Chicago, IL—Chlamydia trachomatis (chlamydia) infection was shown to increase the risk for developing ovarian cancer by approximately 2-fold in 2 independent studies presented at the 2018 American Association for Cancer Research Annual Meeting. In each of the studies, women who had antibodies against pGP3, a protein that is a validated marker of active or previous chlamydia infection, had twice the risk for being diagnosed with ovarian cancer compared with matched controls. Interestingly, no association was observed between antibodies related to other infections and ovarian cancer in either study.

Chlamydia trachomatis Infection Doubles the Risk for Ovarian Cancer

“The fact that there were no associations with antibodies against other infectious agents really supports the specificity of the association of chlamydia infection with ovarian cancer,” said lead investigator Britton Trabert, PhD, MS, Earl Stadtman Investigator, Division of Cancer Epidemiology and Genetics, Metabolic Epidemiology Branch, National Cancer Institute, Bethesda, MD.

She pointed out that pelvic inflammatory disease (PID) is associated with a doubling of the risk for ovarian cancer, and chlamydia infection is the leading cause of PID.

The studies included a Polish population-based case-control study of 278 women diagnosed with ovarian cancer between 2000 and 2003 and 556 matched controls, and the National Cancer Institute–sponsored Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial, a nested case-control prospective trial with blood drawn prior to diagnosis, that included 160 women who developed ovarian cancer during follow-up and 159 matched controls.

at a glance

    
  • Investigators evaluated 2 independent study populations to examine the relationship between chlamydia infection and the risk for ovarian cancer
  • 
  • Both studies showed that women who had antibodies indicating current or previous chlamydia infection had twice the risk of being diagnosed with ovarian cancer than matched control subjects
  • 
  • The risk for ovarian cancer was not associated with antibodies related to other infections

Risk Factors

Dr Trabert and colleagues measured serologic markers of sexually and nonsexually transmitted infections, including chlamydia, human papilloma virus, herpes simplex virus, hepatitis B, and hepatitis C. The antibody to chlamydia, pGP3, was the only one that was significantly associated with ovarian cancer.

Using the traditional laboratory cut-off point for pGP3 indicative of previous chlamydia infection, the odds ratio for developing ovarian cancer was 1.63 in the Polish study and 1.43 in the PLCO trial. Using a more stringent cut-off point for pGP3, the odds ratios were 2.0 and 2.25, respectively.

“This study suggests that the risk for ovarian cancer could potentially be reduced through screening and treatment of chlamydia infection,” Dr Trabert stated. She said that this study does not answer the question of whether treatment of chlamydia infection prevents ovarian cancer, and that her research team is planning a larger study to confirm these findings and to determine whether chlamydia infection has a stronger association with specific subtypes of ovarian cancer.

“We do need to evaluate whether treatment of PID and chlamydia is preventive,” Dr Trabert said.

A limitation of this study is that the multiplex platform used to test for antibodies was not able to provide reliable results about antibodies to Neisseria gonorrhoeae, another established cause of PID.

American Association for Cancer Research Program Chair Elaine R. Mardis, PhD, Professor and Co-Executive Director, Institute for Genomic Medicine, Nationwide Children’s Hospital, Columbus, OH, noted that ovarian cancer is typically silent until it is more advanced and, therefore, is associated with a poor prognosis.

“This study is notable for being an international collaboration between the Polish study and the PLCO to provide tissue samples, and it suggests that we can go a long way toward improving detection of ovarian cancer by routine screening for PID and chlamydia,” Dr Mardis said.

Related Items
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
JHOP Web Exclusives published on August 6, 2018 in Immunotherapy
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Lung Cancer
CAR T-Cell Manufacturing Process Depends on Good-Quality T-Cells
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Breast Cancer
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Breast Cancer
Adjuvant Chemotherapy in Upper-Tract Urothelial Cancer Shows Impressive Gains in the POUT Trial
Phoebe Starr
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in Genitourinary Cancers
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Ovarian Cancer
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Psychological Distress in Patients with Cancer Warrants Attention
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Patients’ Chemotherapy-Related Side-Effect Concerns Have Evolved, But Hair Loss Remains Significant
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Last modified: June 13, 2018